drugset / Trial / NCT07198386

Trial of CS060380 Tablets for Non-alcoholic Steatohepatitis (NASH)

NCT07198386

Phase 2 Recruiting 120 enrolled Cascade Pharmaceuticals, Inc
RandomizedParallel-groupDouble-blindTreatment

Summary

The goal of this clinical trial is to learn if CS060380 tablets works to treat non-alcoholic steatohepatitis(NASH) in adults.It will also learn about the safety of CS060380 tablets.The main questions it aims to answer are: * After 12 weeks of administration, what was the percentage change in fat content evaluated by MRI-PDFF compared to the baseline? * What medical problems do participants have when taking CS060380 tablets? Researchers will compare CS060380 tablets to a placebo (a look-alike substance that contains no drug) to see if CS060380 tablets works to treat NASH. Participants will: * Take CS060380 tablets or a placebo every day for 12 weeks * Visit the clinic for checkups and tests at the frequency required by the protocol * Keep a diary of their symptoms and the number of tablets taken

Timeline

Start
2025-09-30
Primary completion
2026-07-24
Completion
2026-11-30

Drugs

EvaluationDrugModalityDoseRoute
Subject CS060380 Unknown 0.25 mg Oral
Subject CS060380 Unknown 0.5 mg Oral
Subject CS060380 Unknown 1 mg Oral
Subject CS060380 Unknown 2 mg Oral